The 7th CKD (Chronic Kidney Disease Drug Development) Summit covers topics such as:
- Where is the Landscape Heading in Terms of Acceptable Surrogate Endpoints in CKD?
- Varied Heterogeneity Across CKD Populations to Innovate More Precise & Subgroup-Specific Treatments
- Biomarker Innovation to Facilitate Early Phase CKD Trials
- Late Phase Endpoints & Regulatory Acceptance
- Developing Next-Generation Preclinical Models to Recapitulate Human Renal Function & Pathophysiology
- Novel Innovation in Early-Phase Clinical Evaluation of CKD Candidates
- Enhancing Trial Design in Response to the Expanding CKD Market
- The Journey Towards More Personalized Therapies for Rare & Common Kidney Disease Patients
- Combining Patient Insight & Fostering Diversity in Renal Trials
- Availability of Advancing Technologies to Identify New Targets
- Clinical Progress in Regenerative Medicine: Striving Towards a One-Dose Cure for CKD
- Translating New CKD Therapies into Clinical Practice Guidelines in a Rapidly Changing Landscape
- Translating Advanced Drug Delivery Systems to the Clinic for Safe & Specific Renal Targeting
- Current & Potential Immune Targets in Clinical Development for Kidney Disease
- Optimizing Real-World Evidence to Supplement Clinical Studies & Maximizing Payer Support
- What’s Next for CKD Drug Development?
The 7th CKD (Chronic Kidney Disease Drug Development) Summit might be held in Mar 2025.